FDA CLEARS BIOMS MEDICAL FOR PHASE III MULTIPLE SCLEROSIS

摘要

BioMS Medical Corp (TSX: MS),Edmonton,Canada,a leading developer of products for the treatment of multiple sclerosis (MS),has received clearance from the United States Food and Drug Administration (FDA) of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS.